Kaufman, P., Pernas, S., Martin, M., Gil-Martin, M., Gomez Pardo, P., Sara, L., Manso, L., Ciruelos, E., Perez-Fidalgo, J., Hernando, C., Ademuyiwa, F., Weilbaecher, K., Mayer, I., Pluard, T., Martinez Garcia, M., Vahdat, L., Wach, A., Barker, D., Romagnoli, B., & Cortes, J. (n.d.). balixafortide (a CXCR4 antagonist) plus eribulin in HER2-negative metastatic breast cancer (MBC): A Phase I open-label trial. European journal of cancer, 92, S117–S118. http://access.bl.uk/ark:/81055/vdc_100060774057.0x00002f